pemetreksed pharmas 500 mg prašak za koncentrat za otopinu za infuziju
pharmas d.o.o., radnička cesta 47, zagreb, hrvatska - pemetrekseddinatrij hemipentahidrat - prašak za koncentrat za otopinu za infuziju - 500 mg - urbroj: jedna bočica sadrži 500 mg pemetrekseda (u obliku pemetrekseddinatrij hemipentahidrata)
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - asthma; pulmonary disease, chronic obstructive - lijekovi za opstruktivne plućne bolesti dišnih putova, - budesonid / formoterol teva pharma b. je indiciran u odrasloj dobi od 18 godina i stariji. asthmabudesonide/Формотерола tewa pharma b. navodi u redovnom liječenju astme, gdje je upotreba kombinacije (inhalacijskim kortikosteroidima i trajno djeluju β2 адренорецепторов) preporuča:-kod bolesnika adekvatno ne prati ингаляционными kortikosteroidima i "po potrebi" udahnuti короткодействующих β2 адреномиметиков. ili-kod pacijenata već adekvatno prati na oba inhalacijskim kortikosteroidima i trajno djeluju β2 адреномиметиков. copdsymptomatic liječenje bolesnika s kopb, kotor принудили выдыхательный tome u 1 drugom (fev1) .
sunitinib pharmascience 12,5 mg/1 kapsula kapsula, tvrda
evropa lijek pharma d.o.o. - sunitinib - kapsula, tvrda - 12,5 mg/1 kapsula - 1 kapsula, tvrda sadrži: 12,5 mg sunitiniba (u obliku 13,646 mg sunitinib hidrohlorida)
sunitinib pharmascience 12,5 mg/1 kapsula kapsula, tvrda
evropa lijek pharma d.o.o. - sunitinib - kapsula, tvrda - 12,5 mg/1 kapsula - 1 kapsula, tvrda sadrži: 12,5 mg sunitiniba (u obliku 13,646 mg sunitinib hidrohlorida)
sunitinib pharmascience 25 mg/1 kapsula kapsula, tvrda
evropa lijek pharma d.o.o. - sunitinib - kapsula, tvrda - 25 mg/1 kapsula - 1 kapsula, tvrda sadrži: 25 mg sunitiniba (u obliku 27,293 mg sunitinib hidrohlorida)
sunitinib pharmascience 25 mg/1 kapsula kapsula, tvrda
evropa lijek pharma d.o.o. - sunitinib - kapsula, tvrda - 25 mg/1 kapsula - 1 kapsula, tvrda sadrži: 25 mg sunitiniba (u obliku 27,293 mg sunitinib hidrohlorida)
sunitinib pharmascience 50 mg/1 kapsula kapsula, tvrda
evropa lijek pharma d.o.o. - sunitinib - kapsula, tvrda - 50 mg/1 kapsula - 1 kapsula, tvrda sadrži: 50 mg sunitiniba (u obliku 54,585 mg sunitinib hidrohlorida)
sunitinib pharmascience 50 mg/1 kapsula kapsula, tvrda
evropa lijek pharma d.o.o. - sunitinib - kapsula, tvrda - 50 mg/1 kapsula - 1 kapsula, tvrda sadrži: 50 mg sunitiniba (u obliku 54,585 mg sunitinib hidrohlorida)
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
dultavax ≥ 2 i.j./0.5 ml+ ≥ 20 i.j./0.5 ml+ 40 d'ag'u/0.5 ml+ 8 d'ag'u/0.5 ml+ 32 d'ag'u/0.5 ml suspenzija za injekciju u napun
amicus pharma d.o.o. - пропорциональному protiv difterije, poliomijelitisa, tetanusa (inaktivirana), adsorbovana - suspenzija za injekciju u napunjenoj šprici - ≥ 2 i.j./0.5 ml+ ≥ 20 i.j./0.5 ml+ 40 d'ag'u/0.5 ml+ 8 d'ag'u/0.5 ml+ 32 d'ag'u/0.5 ml - jedna doza od 0,5 ml suspenzije za injekciju u napunjenoj šprici sadrži: difterija toksoid ≥ 2 iu tetanus toksoid ≥ 20 iu poliomijelitis virus (inaktivirani) tip 1 poliovirus (mahoney soj) 40 du tip 2 poliovirus (mef1 soj) 8 du tip 3 poliovirus (saukett soj) 32 du (1) adsorbirano na aluminijum hidroksid (0,35 mg)